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INTRODUCTION 
Human obesity has been associated with altered dopamine (DA) functioning (1), altered dopamine D2-
like (D2, D3, D4) receptor binding in brain reward regions (2;3), as well as with altered reward-related 
behavior (4-6). The specific nature of these relations, however, remains unclear. Animal studies have 
demonstrated that the pancreatic hormone insulin binds to insulin receptors and thereby influences 
reward-related behavior. Because human obesity is often linked to insulin dysregulation  (7;8), individual 
differences in insulin sensitivity or secretion, independent of obesity, may relate to D2 receptors and 
reward discounting in humans. 
 
Animal studies have demonstrated that insulin binds directly to insulin receptors located on 
dopaminergic neurons in brain reward pathways (9), and regulates DA signaling, reward processing, and 
reward behavior by increasing dopamine transporter (DAT) density and function (10;11). A dopamine 
D2-like receptor-mediated mechanism may affect this process (12). Insulin increases brain reward 
thresholds (13), and reduces preference for food reward (14), operant responding for food reward (15), 
non-hedonic food intake (16), and hedonic food intake in sated animals (11).  
 
Although the effects of insulin on reward processing and behavior have been demonstrated in animals, 
it is not known whether insulin affects DA-mediated reward-related behavior in humans. Ultimately, 
understanding the precise relations among dopaminergic dysfunction, altered reward-related behavior, 
and metabolic factors will be critical for identifying behavioral subtypes of obesity, and for specifying 
points of clinical intervention along the complex pathway linking neuroendocrine hormones and 
behavior.  
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The goal of the present study was to determine the specific relations among individual differences in 
insulin function, dopamine D2 receptors, and reward choice behavior in healthy obese and normal-
weight adults. We hypothesized that impaired insulin function would relate to impaired reward 
discounting (specifically, greater preference for risky rewards, greater preference for immediate 
rewards) and lower D2R binding in reward regions of interest (ROIs). 
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MATERIALS AND METHODS 
Participants. Obese and normal-weight adults were studied as part of an ongoing, longitudinal 
investigation of dopaminergic function in obesity. After initial screening, individuals were assessed with 
a detailed history, including neurological and physical examinations, psychiatric interviews (Structured 
Clinical Interview for DSM-IV; American Psychiatric Association 1994), and routine blood tests (e.g., 
fasting plasma glucose, lipids, serum creatinine, hematocrit). Individuals were excluded for significant 
personal history of chronic illness (e.g., diabetes and other significant neurological, cerebrovascular, 
cardiovascular, or psychiatric diagnosis) (e.g., major depression, anxiety, eating disorder, and other 
DSM-IV Axis I disorders), head trauma, any dopaminergic drug (e.g., neuroleptics or metoclopramide), 
current heavy alcohol use (males >2 drinks per day, females >1 drink per day) or drug use (17), history of 
substance abuse or dependence, or IQ below 70 (as measured by the Wechsler Scale Adult Intelligence 
Scale (18)). The study was approved by the Washington University School of Medicine Human Research 
Protection Office and the Radioactive Drug Research Committee, and all participants gave informed 
consent prior to participation.  
 
Obesity and insulin measures. All participants underwent a dual-energy x-ray absorptiometry (DXA) 
total body scan to assess body composition (body mass index, BMI kg/m2). Participants also had a 2-hour 
oral glucose tolerance test (OGTT), with arterialized hand vein sampling of insulin, C-peptides, and blood 
glucose levels at times –5, 0, 10, 20, 30, 60, and 120 minutes after drinking a standard 75g Glucola load. 
β-cell function was estimated using  a minimal model derived from the OGTT to calculate a disposition 
index (DI; [insulin sensitivity × insuin secretion for the given amount of glucose]). Disposition index was 
selected as the primary measure of insulin function because it accounts for both how much insulin is 
secreted for a given amount of ingested glucose, and how effective insulin secretion is at clearing 
glucose (19); higher DI indicates better insulin function. The oral glucose minimal model produces insulin 
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sensitivity measures that compare well with insulin sensitivity estimated from an intravenous glucose 
tolerance test (20).  Insulin sensitivity was estimated using the Matsuda insulin sensitivity index 
(Matsuda ISI; (10,000/√[(Glucosett0’ (mg/dL) × Insulint0’ (mU/L)) × (Glucosemean × Insulinmean)]) (21), such 
that higher Matsuda ISI indicates greater insulin sensitivity. Insulin secretion was calculated using 
minimal model analysis (Phi Total), providing an index of insulin secretion in relation to plasma glucose 
that relies on plasma C-peptide as a function of glucose concentration (19), where higher Phi Total 
indicates greater pancreatic β-cell secretion of insulin in response to glucose load.  
 
Image acquisition, preprocessing, and analyses. Participants underwent magnetic resonance (MR) and 
PET scans. Structural MR T1-weighted anatomical images were acquired on a Siemens Magnetom Tim 
Trio 3T scanner using a 3-D MPRAGE sequence (sagittal orientation, TR=2400 ms, TE=3.16 ms, FA=8 
degrees, slab thickness 176mm, FOV=256x256mm; voxel resolution= 1x1x1 mm). PET images were 
acquired on a Siemens/CTI ECAT EXACT HR+ scanner using [11C]NMB, a high-affinity radioligand that is 
highly selective for the dopaminergic D2 receptor over the D3 receptor subtype of the D2 receptor 
family, and importantly, is not displaced by endogenous dopamine (22;23). [11C]NMB was administered 
intravenously to each subject with a specific activity exceeding 2000 Ci/mmol, and an injected mass < 
7.3 µg of NMB.  Regions of interest (ROIs) were selected a priori and identified using FreeSurfer (24), and 
included the caudate, putamen, and nucleus accumbens. Each region, except for the nucleus accumbens 
(due to its small size), was eroded by approximately 2 mm from the surface by combining a Gaussian 
smoothing filter with thresholding to reduce partial volume effects. For each participant, the dynamic 
PET images were co-registered to each other and to the participant’s MPRAGE image as described 
previously (25). ROIs and the cerebellar cortex reference region were resampled in the same atlas space 
(26), and decay-corrected tissue activity curves were extracted for each ROI from the dynamic PET data. 
Dopamine D2R binding potentials (BPND) were determined for each ROI using the Logan graphical 
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method with the whole cerebellum as the reference region (27). Binding potentials were computed for 
each hemisphere and averaged across left and right caudate, putamen, and nucleus accumbens, in order 
to minimize the number of comparisons, and because no evidence suggested that these findings would 
be asymmetric. 
 
Behavioral paradigms and analyses. All participants underwent behavioral testing. Reward discounting 
was assessed using two reliable computerized neuropsychological tasks, a probability reward 
discounting task (PRD) and delay reward discounting task (DRD). Both tasks are thought to be mediated 
by dopamine (28-32), have been associated with distinct neural mechanisms in animals (33;34) and 
decision processes (35;36), and have been used in previous studies of obesity (6;37;38).  
The PRD task was used to assess preference for smaller, certain rewards over larger, riskier rewards. 
Participants were asked to make a series of choices between two hypothetical monetary rewards: a 
smaller, certain reward (to be received “for sure”), and a larger reward to be received with some 
probability (10%, 25%, 50%, 75%, and 90%). The DRD task was used to assess preference for smaller, 
immediate rewards over larger future rewards. Participants were again asked to make a series of 
choices between two hypothetical monetary rewards: a smaller, immediate reward (to be received 
“now”), and a larger reward to be received in the future (1 week, 1 month, 6 month, 1 year, and 2 years 
from now). For both the PRD and DRD tasks, a series of “indifference points” was computed and plotted, 
representing the points at which the two rewards (e.g., the larger reward and the smaller reward) were 
of equal subjective value for an individual at each probability and at each delay interval. The degree of 
probability and delay reward discounting was determined by calculating the area under the curve (AUC) 
(39), an atheoretical measure that reflects the degree to which a reward decreases in subjective value as 
a function of probability (“odds against;” PRDAUC) or delay (DRDAUC) (40). Higher AUC values indicate less 
discounting as a function of probability or delay. 
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Primary statistical analyses. Planned data analyses were conducted using SPSS v. 20.0. To test the 
hypothesis that impaired insulin sensitivity and secretion (low DI) is related to impaired DA functioning 
(low D2R binding potential) in primary reward regions (caudate, putamen, nucleus accumbens), 
Pearson’s partial correlation coefficients were calculated between DI and D2R BPND in each ROI, 
controlling for age, gender, BMI, and education, using a Bonferroni-corrected threshold (p<.02) for 
significance testing; covariates were selected because they have been shown to correlate with 
dependent variables of interest in previous studies (6;37). To test the hypothesis that impaired insulin 
function (lower DI) relates to altered reward choice (greater preference for risky or immediate rewards), 
Pearson’s partial correlation coefficients were calculated between DI and reward choice variables 
(PRDAUC; DRDAUC), controlling for age, gender, BMI, and education. We explored the effects of DI on 
variables of interest by examining relations with Matsuda ISI and Phi Total separately, but only in cases 
when the correlation with DI was significant, in order to minimize the problem of multiple comparisons. 
Bonferroni-corrected thresholds (p<.025) were used for significance testing. Cohen’s effect size 
calculations for each Pearson’s correlation (Cohen’s d; (41)) and for each hierarchical linear regression 
(Cohen’s f2) were completed using StatCalc (42). All analyses were first completed in the total sample 
(obese and normal-weight groups combined). Analyses were then conducted within each group 
separately in order to characterize more precisely any potential relations due to the fact that group 
membership was determined by BMI.  
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RESULTS 
Participants. 14 obese adults (2 male), and 14 normal-weight adults (4 male) were studied. One 
participant in the normal-weight group had a BMI greater than 25 kg/m2 (27.7 kg/m2), however, this 
participant was included in the normal-weight group because other weight parameters (e.g., percent 
body fat) fell into the normal-weight category. PET data for two obese participants were lost due to 
participant attrition, and DRD and PRD data from one obese and one normal-weight subject were lost 
due to computer failure; these four participants were excluded from pair-wise analyses. Descriptive 
statistics are summarized in Table 1.  
 
General Results. Obese and normal-weight participants did not differ in age, education, D2R BPND in 
caudate, putamen, nucleus accumbens, or reward choice (PRDAUC; DRDAUC) after applying Bonferroni 
correction (p <.02 for all comparisons). As expected, obese and normal participants did differ 
significantly in body mass index (p<.001) and insulin measures, Disposition Index (p<.002) and Matsuda 
ISI (p<.001); the group difference in Phi Total was not significant (p=.04) after Bonferroni correction. 
Analyses were based on the hierarchical linear regression model using appropriate covariates (e.g., in 
step two, regressing out BMI when isolating the effects of insulin function, and regressing out insulin 
function when isolating the effects of BMI, after including age, gender, and education in step one).  
Levene’s test for equality of variances revealed that equal variances could be assumed for each variable, 
except for BMI (F=6.17; p=.02), Disposition Index (F=8.37; p<.008), and Matsuda ISI (F= 4.38; p=.05).  
One-sample Kolmogorov-Smirnov tests showed no evidence of non-normality in the distributions of BMI 
within the obese (z=.88; p=.43) and normal-weight (z=.47; p=.98) groups, the Disposition Index within 
the obese (z=.95, p=.33) or normal-weight (z=.91, p=.38) groups, and the Matsuda ISI Index within the 
obese (z=.85, p=.46) or normal-weight (z=.56, p=.91) groups.  
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Relation of D2R BPND to Reward Choice. In the total sample, obese group, and normal-weight group, 
D2R BPND in caudate, putamen, or nucleus accumbens did not correlate with either reward choice 
measure (PRDAUC; DRDAUC), controlling for age, gender, education, BMI, and DI (Table 2). 
 
Relation of D2R BPND to Insulin Function. D2R BPND in caudate, putamen, nucleus accumbens did not 
correlate with DI, controlling for age, gender, BMI, and education (Table 3). 
 
Relation of Insulin Function to Reward Choice. In the combined obese and normal-weight group, DI 
correlated with DRDAUC (r=.495; p=.019; Cohen’s f
2=.32), controlling for age, gender, BMI, and education; 
better insulin function related to greater preference for larger, delayed rewards (Figure 1). This effect 
was driven not primarily by either insulin sensitivity (r=.28; p=.21; Cohen’s f2=.10) or beta cell response 
(r=–.06; p=.80; Cohen’s f2=.003), controlling for age, gender, BMI, and education.  Within the normal-
weight group alone, DI showed a trend-level correlation with DRDAUC (r=.62; p=.08; Cohen’s f
2=.65), 
controlling for age, gender, BMI, and education. Better insulin function may relate to greater preference 
for larger, delayed rewards; but this was only a trend-level correlation (any p<.10 ). There were no 
significant results within the obese group alone (r=.44; p=.23; Cohen’s f2=.25). 
 
In addition, within the obese group alone, DI correlated with PRDAUC (r=–.84; p=.005; Cohen’s f
2=2.40; 
Figure 2A), controlling for age, gender, BMI, and education, such that better insulin function related to 
greater preference for the smaller, more certain reward. Follow-up analyses showed that Matsuda ISI 
correlated with PRDAUC (r=–.67; p=.049; Cohen’s f
2=.81; Figure 2B), but not Phi Total (r=.07; p=.85; 
Cohen’s f2=.03; Figure 2C), controlling for age, gender, BMI, and education, suggesting that better insulin 
sensitivity related to greater preference for the smaller, more certain reward. There were no significant 
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correlations within the combined (r=–.04; p=.87; Cohen’s f2=.001) or normal-weight groups (r=.37; 
p=.34; Cohen’s f2=.15).  
 
Relation of BMI to Reward Choice. To determine whether any relation between BMI and PRDAUC 
existed, independent of insulin function, we correlated BMI with PRDAUC, controlling for age, gender, 
education, and DI. Within the obese group alone, BMI correlated with PRDAUC (r=–.78; p=.01; Cohen’s 
f2=1.57), such that higher BMI related to greater preference for smaller, certain rewards (Figure 3). 
There were no significant correlations within the combined (r=–.10; p=.67; Cohen’s f2=.009) or normal-
weight (r=–.05; p=.90; Cohen’s f2=.002) groups. Finally, to determine whether any relation between BMI 
and DRDAUC existed independent of insulin function, we correlated BMI with DRDAUC, controlling for age, 
gender, education, and DI. There were no significant correlations within the combined (r=.42; p=.054; 
Cohen’s f2=.21), obese (r=–.18; p=.64; Cohen’s f2=.04), or normal-weight groups (r=–.59; p=.10; Cohen’s 
f2=.53). 
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DISCUSSION 
This study demonstrated a relation between insulin function and reward discounting in normal-weight 
and obese adults. The results suggest that insulin function, and insulin sensitivity in particular, relates to 
reward discounting in obese and normal-weight humans, independent of the degree of obesity (BMI).  
 
We examined relations within the obese and normal-weight groups, both combined and separately, and 
tested for between-group differences. First, our results showed that in obese and normal-weight 
participants, better overall insulin function, measured by disposition index (DI) (i.e., a composite 
measure based on the product of insulin sensitivity and β-cell function), related to preference for the 
larger, delayed reward (more patience). To function effectively in many situations, individuals must 
forgo immediate gratification and persist in goal-directed behaviors to achieve some future desired 
outcome. Our results suggest that individuals with good overall insulin function may be better able to 
abstain from immediate, smaller rewards, so as to obtain larger, more delayed rewards; for example, 
choosing a larger lottery payout to be received “later” rather than choosing a reduced lottery payout 
“now” (or, choosing better health “later,” rather than choosing a second ice cream cone “now”).  In 
humans, the directionality of this relation remains unknown. That is, does better insulin function reduce 
the degree of delay reward discounting, or does lower discounting lead to better insulin function? 
Animal studies have shown that, for example, intraventricular insulin reduces non-hedonic food intake 
in sated animals (16), suggesting that insulin levels in healthy non-human animals directly influence 
reward behavior. In humans, this is poorly characterized. 
 
Second, within the obese group, better overall insulin function related to greater preference for smaller, 
certain rewards (more risk aversion). To function effectively in the world, individuals must appropriately 
weigh the risks associated with uncertain rewards. Our results suggest that among obese individuals, 
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those with better overall insulin function may be more likely to select a smaller, certain reward rather 
than a larger, less certain reward. Subsequent analyses showed that the relation between insulin 
function and risk-based reward choice was driven by insulin sensitivity (Matsuda ISI) and not pancreatic 
beta cell response (Phi Total).  The observed pattern may be due to the fact that in the prodrome to 
type 2 diabetes, insulin sensitivity decreases before pancreatic beta cell response diminishes (43), 
suggesting that insulin sensitivity in neurons diminishes before pancreatic function fails overall.  This 
could be the case in our pre-diabetic obese participants who showed poor insulin sensitivity and some 
degree of beta-cell response.  Future studies of obese individuals with type 2 diabetes would provide 
more clarity with respect to these findings. For example, in obese individuals with type 2 diabetes, one 
might expect to see that both insulin sensitivity and pancreatic beta-cell response both contribute to the 
relation between overall insulin function (DI) and reward discounting.  
 
Finally, BMI also was associated with greater preference for smaller, more certain rewards, independent 
of insulin function, but only within obese individuals, suggesting that BMI may contribute independently 
to a lower degree of probability reward choice in obesity. In other words, these data suggest that higher 
BMI contributed to less risk-taking behavior (more risk aversion). Higher-BMI obese individuals made 
less risky choices than did lower-BMI obese individuals. Surprisingly, BMI did not relate to greater delay 
discounting (preference for smaller, more immediate rewards), independent of insulin function. These 
results stand in contrast to previous work. Rasmussen et al. (2010) reported that higher percent body fat 
(PBF), but not BMI, related to greater discounting of probabilistic monetary rewards (44). Weller et al. 
(2008) showed greater delayed reward discounting in obese as compared to leaner women on a 
hypothetical monetary discounting task (37). However, the results of these studies are difficult to 
interpret because studies have found an effect of percent body fat, but not BMI (44), or only in women, 
and not in men (37). These studies also failed to exclude psychiatric and medical conditions (e.g., type 2 
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diabetes) that could confound the interpretation of results. Because of these inconsistent results, we 
believe that our study, which is based on a rigorously screened sample, may be better able to detect 
specific relations among obesity, insulin function, and reward discounting behavior. 
 
Our study suggests that dopamine D2-specific receptor status is not related to BMI, reward discounting 
behavior, or insulin function (as measured by the disposition index; DI), in well-screened adults. This 
result contrasts with previous human studies that have suggested that reduced D2/D3 receptor 
availability in reward regions is related to obesity and pathological reward-driven behavioral phenotypes 
(e.g., drug addiction, cigarette smoking) (45). Our results are also in contrast to animal work showing 
that the effect of insulin on reward may be mediated, in part, through a dopamine D2-like receptor 
mediated mechanism (12). For example, one animal study showed that probability discounting 
correlated with striatal D2/D3 receptor availability, such that high wager sensitivity related to low 
striatal D2/D3 receptor density (46).  The unique receptor-binding properties of the D2-specific ligand, 
[11C]NMB, may provide evidence toward understanding these discrepant findings (22;23). 
 
These previous studies in humans and animals, however, used the radioligands [11C]raclopride or  
[18F]fallypride, which are known to be displaceable by endogenous dopamine or are non-selective for 
D2R versus D3R, confounding potential between-group differences in binding potential differences in 
D2R versus D3R specific binding sites, differences in endogenous dopamine tone or release, or some 
combination of both. This is particularly important when considering the different human brain 
distributions of D2R and D3R (47), and the likely different functional roles of D2R and D3R in reward 
discounting and reward-related behaviors.   
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In addition, it may be the case that BMI, reward discounting behavior, and insulin function more closely 
relate to the dopamine D3 receptor or some other aspect of the midbrain dopamine signaling system 
(e.g., the dopamine transporter) than D2R. Future human studies that examine such specific aspects of 
the midbrain dopamine system are needed to unravel the complex relations among different 
components of the dopamine reward signaling pathway, BMI, reward discounting, and insulin function.  
 
The study has some limitations. First, although our sample size was moderate, it is larger than most of 
the existing human obesity studies of DA receptors and behavior (referenced above). However, based 
on effect sizes from studies of the effects of insulin on cognition (with significant effects ranging from 
Cohen’s d =–.42– to +1.73) (48), this study was sufficiently powered to detect moderate relations 
between insulin and behavior.  Nonetheless, larger and more heterogeneous samples will be needed to 
confirm and extend our findings.  Second, these results are correlational. It is possible that insulin 
dysregulation influenced behavior, or it is possible that individuals with altered reward behavior are 
more likely to have poor eating habits leading to insulin dysregulation. Longitudinal investigation of 
changes in insulin function or weight will be important in understanding the directionality of these 
relations.  However, experiments in nonhuman animals show that insulin can affect reward sensitivity, 
and our data provide the first evidence in humans that insulin function and reward behaviors are related. 
Third, this study did not measure other aspects of DA functioning (e.g., DA tone, presynaptic DA release, 
pre- versus post-synaptic D2R density, D3R BP, DAT membrane density or function) with respect to 
insulin function and behavior. Additional studies will be integral to understanding the complex relations 
among obesity, insulin, midbrain and extrastriatal dopamine signaling systems, other monoamine and 
neuroendocrine signaling systems, functional networks, and reward discounting behavior. 
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Our results demonstrate that, as in animals, the pancreatic hormone insulin is related to reward 
behavior in humans. In particular, better insulin function related to less problematic risk- and delay-
based reward discounting.  In addition, we show that within obese individuals, BMI related to greater 
preference for smaller, more certain rewards, independent of insulin function. We found no significant 
relations between insulin D2R BPND and insulin function, or D2R BPND and reward discounting, in obese 
or normal-weight individuals. Our results suggest that the relations among BMI, metabolic dysfunction, 
and reward discounting may not be primarily mediated by D2 BPND, but may instead relate to other 
aspects of the DA signaling system (e.g., D3R, DAT), likely in concert with other monoaminergic and 
brain regulatory systems. Improving insulin function may provide a novel behavioral treatment target 
for future, more clinically relevant, studies of obesity and weight reduction.   
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TABLES 
 
Table Captions. 
 
Table 1 – Table showing descriptive statistics for obese and normal-weight groups for BMI, 
demographic, and insulin-related measures. ** indicates p<.02. Cohen’s effect sizes (Cohen’s d) 
are shown for each variable. 
Table 2 – Table showing relation between D2R BPND and reward discounting. PET data for two obese 
participants were lost due to no-shows on scan day, and DRD and PRD data from one obese and 
one normal-weight subject were lost due to electronic failure; these participants were excluded 
from relevant pair-wise analyses. Pearson’s partial correlations are shown for the Combined, 
Obese, and Normal-weight participants, controlling for age, gender, education, BMI, and 
Disposition Index (DI).  
Table 3 – Table showing relation between D2R BPND and insulin function. PET data for two obese 
participants were lost due to no-shows on scan day; these participants were excluded from 
relevant pair-wise analyses. Pearson’s partial correlations are shown for the Combined, Obese, 
and Normal-weight participants, controlling for age, gender, education, and BMI.  
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Table 1 – Descriptive Statistics  
  OBESE 
(N=14) 
   NORMAL 
(N=14) 
  Independent 
Samples t-test 
 
 Mean St. Dev. Range  Mean St. Dev. Range  t Cohen’s effect size (d) 
           
BMI (kg/m2) 39.84  4.13 33.7–46.7  22.58  2.31 18.9–27.7  13.65** 5.35 
Age (years) 33.22  6.37 22.7–40.9  29.57  5.65 22.4–39.7  1.66 0.63 
Education (years) 14.93  1.73 12.0–18.0  16.21  1.31 14.0–18.0  –2.22* –0.86 
Matsuda ISI  4.65 3.45 1.23–10.53  12.28 5.68 4.76–21.40  –4.30** –1.69 
Phi Total 39.85 20.43 18.30–95.42  27.12 7.14 15.95–41.24  2.20* 0.86 
Disposition Index (DI)  141.56 72.78 61.33–280.66  329.08 179.76 156.08–758.42  –3.63** –1.42 
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Table 2 – D2R BPND Does Not Relate to Reward Discounting 
  PRD (AUC) DRD (AUC) 
COMBINED OBESE AND NORMAL 
(N=24) 
   
 PRD (AUC)   r=0.03; p=0.89 
 DRD (AUC) r=0.03; p=0.89  
 Putamen D2R BPND r=–0.08; p=0.74 r=–0.29; p=0.22 
 Caudate D2R BPND r=0.18; p=0.45 r=–0.20; p=0.42 
 Nucleus Accumbens  
D2R BPND 
r=0.07; p=0.78 r=–0.17; p=0.49 
OBESE (N=11)    
 PRD (AUC)  r=0.10; p=0.85 
 DRD (AUC) r=0.10; p=0.85  
 Putamen D2R BPND r=0.03; p=0.95 r=–0.58; p=0.29 
 Caudate D2R BPND r=0.07; p=0.90 r=0.11; p=0.83 
 Nucleus Accumbens  
D2R BPND 
r=0.11; p=0.98 r=–0.66; p=0.16 
NORMAL-WEIGHT (N=13)    
 PRD (AUC)  r=–0.28; p=0.50 
 DRD (AUC) r=–0.28; p=0.50  
 Putamen D2R BPND r=0.19; p=0.66 r=0.05; p=0.91 
 Caudate D2R BPND r=0.61; p=0.11 r=–0.28; p=0.50 
 Nucleus Accumbens  
D2R BPND 
r=0.09; p=0.83 r=0.08; p=0.85 
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Table 3 – D2R BPND Does Not Relate to Insulin Function 
  Disposition Index (DI) 
COMBINED OBESE AND NORMAL-WEIGHT (N=26)   
 Putamen D2R BPND r=–0.20; p=0.37 
 Caudate D2R BPND r=0.01; p=0.97 
 Nucleus Accumbens 
D2R BPND 
r=–0.21; p=0.34 
OBESE (N=12)   
 Putamen D2R BPND r=0.37; p=0.37 
 Caudate D2R BPND r=0.48; p=0.23 
 Nucleus Accumbens 
D2R BPND 
r=–0.18; p=0.67 
NORMAL-WEIGHT (N=14)   
 Putamen D2R BPND r=–0.39; p=0.26 
 Caudate D2R BPND r=–0.13; p=0.73 
 Nucleus Accumbens 
D2R B BPND 
r=–0.30; p=0.39 
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Figures 
 
Figure 1 – Scatterplot of scaled score residuals (after regressing age, gender, BMI, and education). 
Greater insulin function related to increased preference for larger, delayed rewards in both 
normal-weight (solid circles) and obese (open circles) individuals (p<0.025). 
Figure 2 – Scatterplot of scaled score residuals (after regressing age, gender, BMI, and education). 
Greater insulin function related to lower preference for risky rewards in obese participants. 
Greater insulin function overall (higher DI; Matsuda ISI × Phi Total) related to increased 
preference for smaller, certain rewards in obese individuals (Figure 2A; Cohen’s f2 = 2.40). 
Greater insulin sensitivity (higher Matsuda ISI) related to increased preference for smaller, 
certain rewards in obese individuals (Figure 2B; Cohen’s f2=.81). Beta-cell function (Phi Total) 
was unrelated to probability discounting (Figure 2C; Cohen’s f2=.65).  
Figure 3 – Scatterplot of scaled score residuals (after regressing age, gender, education, and insulin 
function (DI)). Body mass index (BMI) related to increased preference for larger, riskier rewards 
in obese individuals (Cohen’s f2=1.57). 
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 Figure 1 – Insulin Function Relates to Delay Reward Discounting in Normal-weight and Obese 
Participants 
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Figure 2 – Insulin Function Relates to Probability Reward Discounting in Obese Participants 
A.                                                                         B.                                                                               C. 
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Figure 3 – BMI Relates to Probability Reward Discounting in Obese Participants 
 
